S26 Summary of Findings

| **Hydroxychloroquine plus azithromycin versus standard care for COVID-19** | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Patients or population:** Anyone with a diagnosis of COVID-19  **Setting:** Any setting  **Intervention:** Hydroxychloroquine plus azithromycin  **Comparison:** Standard care | | | | | | |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **No of participants (studies)** | **Certainty of the evidence (GRADE)** | **Comments** |
| **Risk with**  **standard care** | **Risk with**  **hydroxychloroquine plus azithromycin** |
| **All-cause mortality**  *Follow-up: 15 days* | 26 per 1,000 | **14 per 1,000** | - | 444  (1 RCT) | ⨁◯◯◯ VERY LOW a,b,c |  |
| **Serious adverse events**  *Follow-up: 15 days* | 26 per 1,000 | **13 per 1,000** | - | 444  (1 RCT) | ⨁◯◯◯ VERY LOW a,b,c | This data is based on mortality data, as this proportion was higher than the proportion of participants with serious adverse events. |
| **Admission to intensive care** | - | - | - | - | - | Outcome not yet measured or reported |
| **Mechanical ventilation**  *Follow-up: 15 days* | 57 per 1,000 | **92 per 1,000** | - | 444  (1 RCT) | ⨁◯◯◯ VERY LOW a,b,c |  |
| **Renal replacement therapy** | - | - | - | - | - | Outcome not yet measured or reported |
| **Quality of Life** | - | - | - | - | - | Outcome not yet measured or reported |
| **Non-serious adverse events**  *Follow-up: 15 days* | 269 per 1,000 | **378 per 1,000** |  | 444  (1 RCT) | ⨁◯◯◯ VERY LOW a,b,c |  |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  **RR:** Risk ratio; **CI:** Confidence interval; **GRADE:** GRADE Working Group grades of evidence | | | | | | |
| **GRADE Working Group grades of evidence**  **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

**Explanations**

a. Downgraded 2 for risk of bias

b. Downgraded 1 for publication bias/for profit bias as the study was funded by a pharmaceutical company

c. Downgraded 1 for indirectness due to a single study from a single country, therefore results in this population might not be generalizable to other settings